PGK
Desconocido
SYSMALVAC: Identifying correlates of protection to accelerate vaccine trials systems evaluation of two models...
Vaccine development is an empirical process (trial and error) and involves a long, expensive clinical development pipeline to license an eff...
Financiado
Financiado
IBDASE: Mucosal protease and their inhibitors in inflammatory bowel disease From etiopathogenetic insight t...
PROGENIKA BIOPHARMA SA
participó en un
FP7:
IBDase addresses the etiology and pathogenesis of inflammatory bowel disease (IBD) with a multidisciplinary plan for innovative diagnosis an...
Financiado
Financiado
HYPORTH: New approaches in the development of Hypoallergenic implant material in Orthopaedics steps to perso...
PROGENIKA BIOPHARMA SA
participó en un
FP7:
Europe is confronted by a demographic challenge as a decreasing work force has to support an increasing elderly population. The economic ris...
Financiado
Financiado
BEST MS: Best EScalation Treatment in Multiple Sclerosis MS
PROGENIKA BIOPHARMA SA
participó en un
FP7:
"Multiple Sclerosis (MS) is a devastating disease of the central nervous system affecting 2.5 million worldwide. MS is a field of constant t...
Financiado
Financiado
* No se disponen de datos de la empresa actual.